The short answer to the question is yes. I think there are a number of factors, both budgetary and operational.
Around timeliness for our companies, Pharmac doesn't have to make a decision. It doesn't have to say to a submission that's made, “Yes, we will accept this and fund your new medication” or “No, we won't”. One of the things we have pushed long and hard for is to have timelines in place so that if the answer is no, a company can stop negotiating with Pharmac, which is a very time-consuming thing, and just move on to whatever is next in the pipeline.
Pharmac has been very resistant to putting any sorts of timelines in place at all. We believe that if you can't get to the point where your negotiation is complete in 18 months, you probably don't have something that's worth negotiating over.
Pharmac likes stringing these negotiations out for longer because the patent period during that time becomes smaller, and if they do eventually decide to fund something, the cost isn't going to be so great.